As The Block Firm previously revealed, Breckenridge Pharmaceutical, Inc. has recalled at least 50 million tablets of Duloxetine due to the presence of nitrosamines, potent carcinogens, in excess of FDA levels. As a result, The Block Firm filed a class action on behalf of Duloxetine patients, seeking to hold Breckenridge accountable for selling adulterated drugs.
The Duloxetine recall has now significantly expanded. In separate actions, the FDA announced a recall of over 18 million more pills associated with Breckenridge’s drug application. See links here and here.
As we argue in the Breckenridge class action lawsuit, the scale of adulteration—approximately 70 million pills to date, and possibly many more—appears to reflect a systematic disregard for drug safety and quality. Please contact The Block Firm if you are interested in learning more about how we hold irresponsible drug companies accountable when they cut corners on patient safety
